U.S. markets closed
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • Dow 30

    33,761.05
    +424.38 (+1.27%)
     
  • Nasdaq

    13,047.19
    +267.27 (+2.09%)
     
  • Russell 2000

    2,016.62
    +41.36 (+2.09%)
     
  • Crude Oil

    91.88
    -2.46 (-2.61%)
     
  • Gold

    1,818.90
    +11.70 (+0.65%)
     
  • Silver

    20.83
    +0.49 (+2.39%)
     
  • EUR/USD

    1.0257
    -0.0068 (-0.66%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • USD/JPY

    133.4800
    +0.4810 (+0.36%)
     
  • BTC-USD

    24,614.91
    -191.18 (-0.77%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ARCA biopharma Inc (NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19.

  • In the 160-patient trial, both doses of rNAPc2 demonstrated a treatment benefit; however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D-dimer level from Baseline to Day 8 compared to standard of care heparin.

  • The pooled lower and higher rNAPc2 dose groups demonstrated a reduction in D-dimer levels of 16.8% versus 11.2% for the standard of care heparin.

  • The treatment effects of rNAPc2 and heparin were different in mild versus severe categories, with generally decreasing D-dimer levels from baseline in mild patients.

  • But in severe patients, D-dimer levels were increasing in the Heparin group with no change in the rNAPc2 groups.

  • On the secondary endpoint related to eligibility for hospital discharge, the rNAPc2 combined arms log-rank hazard ratio was 0.88 compared to heparin, representing a one-day reduction in time-to-recovery.

  • The thrombosis events component of the composite clinical outcome endpoint yielded nine events in the heparin group versus six in the combined rNAPc2 groups; neither results were statistically significant.

  • rNAPc2 was well-tolerated at both doses. There were no serious treatment-related adverse events, and no dose-dependent increase in adverse events was observed.

  • Price Action: ABIO shares are down 24.4% at $1.74 during the premarket session on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.